Viliam Pavliak

Viliam Pavliak has a vast and diverse work experience in the field of vaccine development. Viliam started their career as a Visiting Fellow at the National Institute of Diabetes and Digestive and Kidney Diseases, where they studied carbohydrate antigen-antibody interactions. Viliam then worked as a Research Associate at the National Research Council Canada, focusing on structural studies of bacterial LPS and capsular polysaccharides.

Pavliak continued their career at Univax Biologics Inc as a Senior Research Scientist, developing group B Streptococcus conjugate vaccines. Viliam then moved to Nabi, where they served as a Senior Research Scientist, leading the development and evaluation of vaccines for Staphylococcus epidermidis and Enterococcus.

At Wyeth Research, Pavliak held the positions of Principal Scientist and Associate Director. Viliam played a crucial role in the research and early development of conjugate vaccines, developing processes for purification and characterization of polysaccharide antigens, as well as chemistries for the preparation of conjugate vaccines.

Pavliak joined Pfizer as an Associate Director and later became a Director, managing analytical and characterization groups involved in the development and performance of release and characterization assays for vaccine candidates. Viliam also served as an analytical liaison for the vaccine early development group and coordinated analytical R&D activities for multiple vaccine programs.

In 2016, Pavliak joined the International Vaccine Institute (IVI) as a Senior Advisor and later became the Head of Vaccine Development. At IVI, they contributed to all areas of the vaccine spectrum, from new vaccine design in the laboratory to vaccine development and evaluation in the field to facilitating sustainable introduction of vaccines in developing countries.

Pavliak also served as a Member of the Scientific Advisory Board at GlycoNet, where they contributed to the organization's vision and mission of delivering solutions to important health issues through glycomics research.

Most recently, Pavliak worked at the Bill & Melinda Gates Medical Research Institute as the Vaccine Process Development and Manufacturing Leader.

Throughout their career, Pavliak has demonstrated a strong commitment to vaccine research and development, with a particular focus on glycomics and improving global public health.

Viliam Pavliak pursued their education in the field of Biochemistry. In 1978, they enrolled at Slovenská technická univerzita v Bratislave and obtained their MSc. degree in Biochemistry in 1982. Viliam decided to continue their academic journey and further specialize in the same field. From 1983 to 1988, Viliam Pavliak pursued their PhD at Slovenská technická univerzita v Bratislave, ultimately receiving their doctoral degree in Biochemistry.